Publications

In this real-world study, Baraliakos, et al. SC IFX demonstrated clinical effectiveness in both
r- and nr-axSpA, with consistent results across diverse patient characteristics. Both physicians and patients reported high satisfaction with no new safety concerns. Authors assessed the real-world outcomes of CT-P13 SC (SC IFX) as treatment for both r- and
nr-axSpA.

Salvato et al. showed that the combination of GC and b/tsDMARDs did not provide additional clinical benefits after 12 months, suggesting that chronic GC use alongside advanced therapies should be avoided. Authors assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAKi compared to other mechanisms of action (OMA) therapies in a cohort of RA patients with inadequate response to TNFi.

Bakay et al. report  that upadacitinib (UPA) demonstrated sustained efficacy across musculoskeletal and skin domains in PsA patients with prior inadequate response to TNF inhibitors, with a safety profile consistent with previous reports.  Authors conducted a retrospective, single-centre observational study evaluating musculoskeletal disease activity, psoriasis, and patient-reported outcomes following initiation of UPA.

Gollins et al. reported that within this cohort, the Psoriatic arthritis response criteria (PsARC) response to 4^th+ lines of b/tsDMARD was not significantly reduced compared with 2^nd/3^rd line in participants who had failed at least 3 b/tsDMARDs. Authors evaluated the primary clinical response to sequential lines of b/tsDMARD therapy in PsA, focusing on the effectiveness of later line treatments.

Kameda et al. reported that UPA treatment sustained efficacy with no new safety signals identified through 5 years of treatment and is a long-term treatment option for Japanese patients with RA and an inadequate response to csDMARDs. Authors present the full 5-year efficacy and safety data for upadacitinib obtained in the SELECT-SUNRISE study.

Diamanti et al. showed that after 12 months of UPA treatment, a substantial proportion of RA patients achieved combined clinical and US remission, independent of prior bDMARD use or monotherapy. In the preliminary data from the UPARAREMUS study, authors reported efficacy of UPA in achieving both clinical and US remission up to 24 weeks in 60 RA patients.

Data by Flouri et al. support greater drug persistence with secukinumab than with TNF inhibitors in patients with axSpA and peripheral spondyloarthritis, both with respect to efficacy- and safety-related discontinuations, while the achievement of 6-month treatment targets was comparable. Flouri et al. compared long term treatment persistence, efficacy and safety between secukinumab and TNF inhibitors in a cohort of patients with SpA treated in real life.

Bai et al. reported that JAKi therapy was associated with a reduced risk of incident uveitis compared with TNF inhibitors among patients with AS, PsO, or PsA. Authors conducted a large-scale, real world comparative study which evaluated the risk of incident uveitis among patients with psoriatic disease and AS treated with either TNFi or JAKi.

Ramiro et al. show that bimekizumab (BKZ) reduces enthesitis and peripheral arthritis in patients with nr-axSpA and r-axSpA up to 2 years. Authors assessed the effect of BKZ treatment on the main peripheral manifestations of axSpA, including enthesitis and peripheral arthritis, using a range of measures including DAPSA, to Week 104 in the BE MOBILE 1 and 2 studies.